Advertisement

Irish firm co-founded by Prof Luke O'Neill bought by healthcare giant for €380m

Professor Luke O'Neill said his company hopes a medicine they developed can stop diseases such as...
Stephen McNeice
Stephen McNeice

16.28 21 Sep 2020


Share this article


Irish firm co-founded by Prof...

Irish firm co-founded by Prof Luke O'Neill bought by healthcare giant for €380m

Stephen McNeice
Stephen McNeice

16.28 21 Sep 2020


Share this article


Professor Luke O'Neill said his company hopes a medicine they developed can stop diseases such as Parkinson's and Alzheimer's 'in their tracks'.

It comes as the Irish biotech co-founded by Professor O'Neill and Australian researcher Professor Matt Cooper has been acquired by Swiss healthcare giant Roche in a landmark deal worth €380 million.

Inflazome develops treatments for inflammatory diseases, and it was set up four years ago after a collaboration between the University of Queensland and Trinity College Dublin.

Advertisement

Speaking on The Pat Kenny Show, Professor O'Neill said the most important thing is that the sale - which is seen as one of the largest in Irish biotech history - benefits patients.

Irish firm co-founded by Prof Luke O'Neill bought by healthcare giant for €380m

00:00:00 / 00:00:00

    

He observed: "We found a very interesting medicine, that can treat inflammatory diseases - and then we've been bought by Roche.

"We needed to get bought, because they can take it to patients - that's the really good news... it's tremendously exciting.

"We're talking about Alzheimer's, Parkinson's, cardiovascular disease."

He said all those diseases "seem to involve one thing that goes wrong in the body", and their drug aims to correct it.

'Stopping Parkinson's in its tracks'

Professor O'Neill said the investors spent around €55 million on the company so far and are now set for a big return, while Trinity College is also set to benefit.

He observed: "Can you imagine if we find a treatment for Parkinson's? That's a devastating disease.

"There are no treatments, almost - there are some treatments that slow it down a bit. We think our treatment might stop Parkinson's in its tracks, and Alzheimer's.

"These two are inflammatory diseases of the brain - your brain is on fire, almost, and our drug can put that fire out."

Professor O'Neill said proving the effectiveness of the drug will cost an "awful lot of money" in trials - and a big company is needed to fund the necessary testing.

He added: "An Irish company found this drug, and then Roche said 'we want to partner with you guys'. It's fantastic we can have this partnership with them.

"Michael J Fox [Foundation] are delighted as well, because they invested in us... they were helping fund some of our work. What they want is to see this [given to] patients as soon as possible, to treat patients with Parkinson's."


Share this article


Read more about

Alzheimer's Luke O'Neill Medicine Parkinson's Roche

Most Popular

Live: Title

Now playing

00:00:00 / 00:00:00
Added to queue
Removed from queue

On Air

Share

Share


Up next

Episode title
Show
Duration

You currently have no podcasts in your queue.

Go to podcasts

On Air

Off The Ball

Off The Ball

19:00-22:00

Share

Up next

THE TOM DUNNE SHOW

THE TOM DUNNE SHOW

22:00-00:00

Share

BEST OF NEWSTALK

BEST OF NEWSTALK

00:00-06:00

Share

BREAKFAST BRIEFING

BREAKFAST BRIEFING

06:00-06:30

Share

BREAKFAST BUSINESS

BREAKFAST BUSINESS

06:30-07:00

Share

NEWSTALK BREAKFAST

NEWSTALK BREAKFAST

07:00-09:00

Share

THE PAT KENNY SHOW

THE PAT KENNY SHOW

09:00-12:00

Share

LUNCHTIME LIVE

LUNCHTIME LIVE

12:00-14:00

Share

MONCRIEFF

MONCRIEFF

14:00-16:00

Share

THE HARD SHOULDER

THE HARD SHOULDER

16:00-19:00

Share

OFF THE BALL

OFF THE BALL

19:00-22:00

Share

00:00:00 / 00:00:00

Share on